Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke

Journal of Clinical Pharmacology

Volumn 47, Issue 4, 2007, Pages 445-452

  Ishibashi, Hideyasu ^a   Creed Pettigrew, L ^b   Funakoshi, Yosuke ^a   Hiramatsu, Makoto ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Arundic acid; Astrocyte; Cerebral ischemia; Pharmacokinetics

Indexed keywords

ARUNDIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; ASTROCYTE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG INFUSION; FEMALE; GROUPS BY AGE; HALF LIFE TIME; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ASTROCYTES; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OCTANOIC ACIDS;

EID: 33947538172     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006299090     Document Type: Article

References (12)

1. Mackay J., Mensah GA The Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health Organization ; 2004.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995 ; 333: 1581-1587.
3. Smith WS, Sung G., Starkman S., et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. Stroke. 2005 ; 36: 1432-1438.
4. Heiss WD, Thiel A., Grond M., Graf R. Which targets are relevant for therapy of acute ischemic stroke ? Stroke. 1999 ; 30: 1486-1489.
5. Asano T., Mori T., Shimoda T., et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets. 2005 ; 4: 127-142.
6. Pettigrew LC, Kasner SE, Albers GW, et al. Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci. 2006 ; 251: 50-56.
7. Brott T., Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989 ; 20: 864-870.
8. Gough K., Hutchison M., Keene O., et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Information J. 1995 ; 29: 1039-1048.
9. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Studies in support of special populations: Geriatrics E7. Current Step 4 version; 24 June 1993.
10. Schmucker DL Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001 ; 18: 837-851.
11. Gladstone DJ, Black SE, Hakim AM Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002 ; 33: 2123-2136.
12. Fisher M., Brott TG Emerging therapies for acute ischemic stroke: new therapies on trial. Stroke. 2003 ; 34: 359-361.